| Patient ID | Sex | Diagnosis | Age | Tumor Stage | Tumor grade | Disease Status | Relapse Type | Survival Status | Survival Time | Missense Mutation - KRAS | Missense Mutation - TP53 | Missense Mutation - CDKN2A | Missense Mutation - SMAD4 | hidden | hidden | hidden | hidden |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DO52120 | Male | PNET | 44 | IV | G2 | Progression | Distant recurrence/metastasis | Deceased | 579 | No | No | No | No | 2 | No | No | DO52120 |
| DO52122 | Female | PNET | 43 | IB | G1 | Stable | NA | Alive | 1986 | No | No | No | No | 6 | No | No | DO52122 |
| DO52123 | Male | PNET | 56 | IV | G2 | Progression | Distant recurrence/metastasis | Alive | 5415 | No | No | No | No | 15 | No | No | DO52123 |
| DO52124 | Male | PNET | 58 | IV | G2 | Progression | Local recurrence and distant metastasis | Deceased | 2359 | No | R248Q,R155Q,R116Q | No | No | 7 | No | Yes | DO52124 |
| DO52125 | Male | PNET | 79 | IV | G1 | Progression | Local recurrence and distant metastasis | Deceased | 140 | No | No | No | No | 1 | No | No | DO52125 |
| DO52126 | Male | PNET | 50 | IIA | G2 | Progression | Distant recurrence/metastasis | Alive | 4346 | No | No | No | No | 12 | No | No | DO52126 |
| DO52127 | Female | PNET | 41 | IIB | G2 | Progression | Distant recurrence/metastasis | Alive | 4260 | No | No | No | No | 12 | No | No | DO52127 |
| DO52128 | Male | PNET | 42 | IV | G1 | Progression | Local recurrence | Alive | 2771 | No | No | No | No | 8 | No | No | DO52128 |
| DO52129 | Female | PNET | 46 | III | G2 | Progression | Distant recurrence/metastasis | Alive | 2828 | No | No | No | No | 8 | No | No | DO52129 |
| DO52131 | Male | PNET | 38 | IV | G1 | Progression | Distant recurrence/metastasis | Alive | 3576 | No | No | No | No | 10 | No | No | DO52131 |
| DO52132 | Female | PNET | 71 | IV | G3 | Progression | Local recurrence and distant metastasis | Deceased | 287 | No | No | No | No | 1 | No | No | DO52132 |
| DO52134 | Male | PNET | 71 | III | G2 | Progression | Local recurrence and distant metastasis | Alive | 3319 | No | No | No | No | 10 | No | No | DO52134 |
| DO52135 | Female | PNET | 47 | IIA | G1 | Stable | NA | Alive | 2054 | No | No | No | No | 6 | No | No | DO52135 |
| DO52136 | Female | PNET | 70 | III | G2 | Progression | Distant recurrence/metastasis | Alive | 3186 | No | No | No | No | 9 | No | No | DO52136 |
| DO52137 | Female | PNET | 30 | IV | G2 | Progression | Local recurrence and distant metastasis | Deceased | 1570 | No | No | No | No | 5 | No | No | DO52137 |
| DO52139 | Female | PNET | 61 | IIB | G2 | Stable | NA | Alive | 1542 | No | No | No | No | 5 | No | No | DO52139 |
| DO52140 | Male | PNET | 63 | III | G1 | Stable | NA | Alive | 789 | No | No | No | No | 3 | No | No | DO52140 |
| DO52141 | Female | PNET | 46 | IA | G2 | Stable | NA | Alive | 1187 | No | No | No | No | 4 | No | No | DO52141 |
| DO52142 | Female | PNET | 62 | IIA | G1 | Stable | NA | Alive | 1140 | No | No | No | No | 4 | No | No | DO52142 |
| DO52143 | Male | PNET | 59 | IB | G2 | Progression | Distant recurrence/metastasis | Alive | 1224 | No | No | No | No | 4 | No | No | DO52143 |
| DO52144 | Male | PNET | 71 | IIA | G1 | Progression | Distant recurrence/metastasis | Alive | 670 | No | No | No | No | 2 | No | No | DO52144 |
| DO52146 | Male | PNET | 75 | IIB | G2 | Stable | NA | Alive | 1152 | No | No | No | No | 4 | No | No | DO52146 |
| DO52147 | Male | PNET | 48 | IB | G2 | Progression | Distant recurrence/metastasis | Alive | 1068 | No | No | No | No | 3 | No | No | DO52147 |
| DO52148 | Male | PNET | 64 | IA | G1 | Stable | NA | Alive | 1187 | No | No | No | No | 4 | No | No | DO52148 |
| DO52149 | Female | PNET | 66 | IIB | G1 | Stable | NA | Alive | 541 | No | No | No | No | 2 | No | No | DO52149 |
| DO52150 | Male | PNET | 40 | IV | G2 | Progression | Distant recurrence/metastasis | Alive | 1097 | No | No | No | No | 4 | No | No | DO52150 |
| DO52151 | Male | PNET | 56 | III | G2 | Progression | Distant recurrence/metastasis | Alive | 1096 | No | No | No | No | 4 | No | No | DO52151 |
| DO52152 | Female | PNET | 44 | IB | G1 | Stable | NA | Alive | 1082 | No | No | No | No | 3 | No | No | DO52152 |
| DO52153 | Male | PNET | 57 | IB | G2 | Stable | NA | Alive | 1068 | No | No | No | No | 3 | No | No | DO52153 |
| DO52154 | Male | PNET | 71 | IB | G1 | Stable | NA | Alive | 1062 | No | No | No | No | 3 | No | No | DO52154 |
| DO52155 | Male | PNET | 60 | IV | G3 | Progression | Local recurrence and distant metastasis | Alive | 757 | No | No | No | No | 3 | No | No | DO52155 |
| DO52156 | Male | PNET | 53 | IV | G1 | Progression | Distant recurrence/metastasis | Alive | 1007 | No | No | No | No | 3 | No | No | DO52156 |
| DO52158 | Male | PNET | 55 | IA | G1 | Stable | NA | Alive | 1007 | No | No | No | No | 3 | No | No | DO52158 |
| DO52159 | Male | PNET | 50 | III | G1 | Stable | NA | Alive | 986 | No | No | No | No | 3 | No | No | DO52159 |
| DO52161 | Male | PNET | 69 | III | G3 | Stable | NA | Deceased | 3 | No | R280K,R148K | No | No | 1 | No | Yes | DO52161 |
| DO52162 | Female | PNET | 20 | IIB | G2 | Stable | NA | Alive | 956 | No | No | No | No | 3 | No | No | DO52162 |
| DO52164 | Male | PNET | 66 | III | G2 | Progression | Local recurrence and distant metastasis | Alive | 803 | No | No | No | No | 3 | No | No | DO52164 |
Overview
Patient Statistics
Tumour Statistics
Cohort Summary
Variant Identification
Drug Prediction
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ARID1A | Q1584* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q1584* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q1584* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q1584* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PTEN | R233* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R233* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R233* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | R233* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | R233* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | R233* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R233* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R233* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R233* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | R233* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R233* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R233* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | R233* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R233* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R233* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R233* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | R233* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R233* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R233* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R233* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R233* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R233* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R233* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R233* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R233* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PDGFRA | intron_variant), PDGFRA MUT* (intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| BRAF | intron_variant | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | intron_variant | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | intron_variant | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | intron_variant | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ESR1 | intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ESR1 | intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), E | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | intron_variant), ABL1 MUT* (intron_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| FGFR2 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | R248Q | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | intron_variant), ROS1 MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | intron_variant), ROS1 MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | intron_variant), ROS1 MUT* (intron_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | intron_variant), ROS1 MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | intron_variant), ROS1 MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | intron_variant), MET MUT* (intron_variant), MET MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NTRK1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | intron_variant | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | intron_variant | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | intron_variant | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| BRD4 | intron_variant | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| BCR | intron_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | intron_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | intron_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NTRK3 | intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| EGFR | intron_variant), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| AKT3 | intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | 3-UTRSNV | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| JAK2 | intron_variant | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ESR1 | intron_variant), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| FGFR2 | intron_variant), FGFR2 MUT* (intron_variant | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | intron_variant), FGFR2 MUT* (intron_variant | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| RAF1 | intron_variant | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | intron_variant | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | intron_variant | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | intron_variant), MLL MUT* (intron_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | intron_variant | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | intron_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | intron_variant | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | intron_variant | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | intron_variant | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | intron_variant | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | intron_variant | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | intron_variant | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| KMT2A | intron_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | intron_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | intron_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | intron_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | intron_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | intron_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | intron_variant), NOTCH2 MUT* (intron_variant), NOTCH2 MUT* (intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | M471T | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | M471T | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| AKT3 | intron_variant | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| VHL | splice_donor_variant | Complete Match | VEGFR inhibitor | Responsive | R | Pre-clinical |
| ERBB4 | intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ARID1A | Q2100* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q2100* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q2100* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q2100* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | intron_variant), NTRK3 MUT* (intron_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| PML | intron_variant | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | intron_variant | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | intron_variant | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| TSC2 | splice_acceptor_variant | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Case report |
| TSC2 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RA, GCA | FDA guidelines |
| TSC2 | splice_acceptor_variant | Complete Match | SRC inhibitor | Responsive | LAM | Pre-clinical |
| TSC2 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | BLCA | Early trials |
| TSC2 | splice_acceptor_variant | Complete Match | MTOR inhibitor | Responsive | RA | Early trials |
| TSC2 | splice_acceptor_variant | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | THCA | Case report |
| TSC2 | splice_acceptor_variant | Different Alteration | SRC inhibitor | Responsive | LAM | Pre-clinical |
| JAK2 | intron_variant), JAK2 MUT* (intron_variant | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| SETD2 | Q2329* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | Q2329* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | intron_variant | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| NOTCH1 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | intron_variant | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| CDKN1A | CdsStartSNV | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1A | CdsStartSNV | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (R1683Q | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | intron_variant), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (R1683Q | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| MET | T618T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| RET | intron_variant | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | intron_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | intron_variant | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | intron_variant | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | intron_variant | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | intron_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | intron_variant | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | intron_variant | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | intron_variant | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PTEN | G209* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | G209* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | G209* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | G209* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | G209* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | G209* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | G209* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | G209* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | G209* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | G209* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | G209* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | G209* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | G209* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | G209* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | G209* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | G209* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | G209* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | G209* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | G209* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | G209* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | G209* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | G209* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | G209* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | G209* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | G209* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ESR1 | IntronicBlockSubstitution), ESR1 MUT* (intron_variant | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | R280K | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R280K | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R280K | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R280K | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R280K | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R280K | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R280K | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R280K | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R280K | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280K | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R280K | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280K | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | intron_variant), MET MUT* (intron_variant), MET MUT* (A320G), MET MUT* (intron_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NRG1 | E478E), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | E478E), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S229*), PTEN MUT (splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Drug-Gene Interactions help
Druggable categories in the cohort
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| ATM | CIViC | TEMOZOLOMIDE | TEMOZOLOMIDE | CHEMBL810 | |
| ATM | CIViC | NU7441 | CHEMBL188678 | CHEMBL188678 | |
| ATM | CKB | Fludarabine | FLUDARABINE | CHEMBL1568 | |
| ATM | CKB | Bendamustine | BENDAMUSTINE | CHEMBL487253 | |
| ATM | CKB | Talazoparib | TALAZOPARIB | CHEMBL3137320 | |
| ATM | CGI | inhibitor | |||
| ATM | CGI | CHK1 | |||
| ATM | CKB | AZD6738 | AZD-6738 | CHEMBL3545178 | |
| ATM | CKB | YU238259 | |||
| ATM | ClearityFoundationBiomarkers | RUCAPARIB | RUCAPARIB | CHEMBL1173055 | |
| ATM | GuideToPharmacologyInteractions | inhibitor | KU-60019 | ||
| ATM | CIViC | SELUMETINIB (AZD6244) | SELUMETINIB | CHEMBL1614701 | |
| ATM | CIViC | OLAPARIB | OLAPARIB | CHEMBL521686 | |
| ATM | CKB | VX-970 | VX-970 | CHEMBL3545202 | |
| ATM | GuideToPharmacologyInteractions | inhibitor | ATM/ATR KINASE INHIBITOR | CHEMBL1221601 | CHEMBL1221601 |
| ATM | CKB | Ibrutinib | IBRUTINIB | CHEMBL1873475 | |
| ATM | GuideToPharmacologyInteractions | inhibitor | VE-822 | ||
| ATM | CKB | Cisplatin | |||
| ATM | CGI | Irinotecan | IRINOTECAN | CHEMBL481 | |
| ATM | CGI | Cisplatin | |||
| ATM | GuideToPharmacologyInteractions | inhibitor | CP466722 | ||
| ATM | CGI | CHK1/2 inhibitor | |||
| ATM | CKB | Valproic Acid | VALPROIC ACID | CHEMBL109 | |
| ATM | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| ATM | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| ATM | CIViC | KU-0060648 | CHEMBL1086377 | CHEMBL1086377 | |
| ATM | ClearityFoundationBiomarkers | E7449 | |||
| ATM | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| ATM | CKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| ATM | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| ATM | CKB | Binimetinib | BINIMETINIB | CHEMBL3187723 | |
| ATM | CKB | E7449 | |||
| ATM | CKB | Veliparib | VELIPARIB | CHEMBL506871 | |
| ATM | CGI | Olaparib | OLAPARIB | CHEMBL521686 | |
| ATM | CKB | Vandetanib | VANDETANIB | CHEMBL24828 | |
| ATM | ClearityFoundationBiomarkers | OLAPARIB | OLAPARIB | CHEMBL521686 | |
| ATM | CIViC | TRAMETINIB | TRAMETINIB | CHEMBL2103875 | |
| ATM | CGI | Temozolomide | TEMOZOLOMIDE | CHEMBL810 | |
| ATM | ClearityFoundationBiomarkers | NIRAPARIB | NIRAPARIB | CHEMBL1094636 | |
| ATM | CGI | AZD6738 | AZD-6738 | CHEMBL3545178 | |
| ATM | GuideToPharmacologyInteractions | inhibitor | KU-55933 | KU-55933 | CHEMBL222102 |
| ATM | CGI | 2 | QUINPIROLE | CHEMBL240773 | |
| ATM | ClearityFoundationBiomarkers | VELIPARIB | VELIPARIB | CHEMBL506871 | |
| ATM | OncoKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| ATM | ClearityFoundationBiomarkers | BMN673 | TALAZOPARIB | CHEMBL3137320 |
Phenotype
Protein
DrugThere are Blood (Plasma, Serum, Buffy coat), FFPE tissue, Fresh frozen tissue samples from unique donors available at PCRFTB, based on the selected clinical filters (Age, Sex, Race, Diagnosis). Researchers can request for samples by submitting an Expression of Interest to PCRFTB.
Overview
Sex
Race
Diagnosis
Tumor stage
Age at Diagnosis